Regenerative medicine

Cellino Announces Ed Tekeian as Senior Vice President of Engineering

Retrieved on: 
Monday, March 18, 2024
Health, Stem Cells, Genetics, Other Health, General Health, Biotechnology, Software as a service, Computer science, Sample, 3M, Tufts University, Patient, Brontes Technologies, SVP, Radiosurgery, 3D, Software, Senior, Varian Medical Systems, Regenerative medicine, Multimedia, FDA, Nursing

Cellino Biotech, Inc. , a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering.

Key Points: 
  • Cellino Biotech, Inc. , a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering.
  • View the full release here: https://www.businesswire.com/news/home/20240318321537/en/
    Ed Tekeian, SVP of Engineering at Cellino (Photo: Business Wire)
    “We are thrilled to welcome Ed, who will bring deep multidisciplinary engineering leadership experience, in addition to strong acumen developing products used by hundreds of thousands of patients,” said Matthias Wagner, Co-Founder & Chief Technology Officer, Cellino.
  • Prior to joining Cellino, Ed was the Head of Software at Formlabs, where he led an integrated software team in developing user-facing applications for 3D printing.
  • Ed holds an MS in Computer Science from Tufts University.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Retrieved on: 
Wednesday, March 13, 2024
Health, Medical Devices, Health Technology, Genetics, Research, Science, Biotechnology, Chiyoda, Tokyo, Ricoh, B cell, Gene editing, Cell, Drug discovery, Intelligence, Acceleration, Patient, RNA, DNA, Acquisition, Messenger, Sumitomo Corporation, IPS, Regenerative medicine, Multinational corporation, Genomics, CRISPR, Drug development, Cas9, Vaccine

Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

Key Points: 
  • Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
  • In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA).
  • Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
  • Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.

Induced Pluripotent Stem Cells Market Report, Featuring Historical Revenue Data for 2021 and 2022, Estimated Figures for 2023, and Compound Annual Growth Rates (CAGRs) through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Cell, Stem cell, Fibroblast, B cell, Enzyme, Serum, Drug discovery, Row, Good manufacturing practice, Differentiable function, Neuron, GMP, Hepatocyte, Regenerative medicine, Medium (website), Antibody, Drug development, Geography, Astrocyte, IPSC, Endothelium

For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.

Key Points: 
  • For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
  • The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW).
  • The report will provide details with respect to induced pluripotent stem cells.

BIO KOREA 2024: Registration Open for Business Partnering

Retrieved on: 
Monday, March 11, 2024
Technology, Research, Business, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Online, COVID-19, BIO, OPA, FCA, Regenerative medicine, Labcorp, Business partnering, Yuhan

BIO KOREA 2024 , jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).

Key Points: 
  • BIO KOREA 2024 , jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).
  • Business Partnering, one of the major programs at BIO KOREA, provides opportunities for one-on-one meetings between companies at home and abroad, alongside pertinent institutions within the BioHealth sector.
  • This year, the Business Partnering Center will be expanded to provide more opportunities for participating companies to make business connections.
  • Throughout the three-day event from May 8 (Wed.) to May 10 (Fri.), the Business Partnering will unfold both online and offline on the sidelines of BIO KOREA 2024.

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Retrieved on: 
Monday, March 11, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ovarian cancer, Regenerative medicine, Patient, City, CIRM, Woman, Neoplasm, Cancer, Safety, Division, FDA, Dove Medical Press, NSC, Pharmaceutical industry

CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.

Key Points: 
  • CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.
  • This proposed CLD-101 treatment utilizes a neural stem cell line to deliver an oncolytic adenovirus directly to abdominal ovarian tumor sites.
  • In this trial, CLD-101 demonstrated safety and the stimulation of an anti-tumor response, with results published in Lancet Oncology .
  • Aboody has financial interest in and is a paid advisory board member for Calidi Biotherapeutics.

REGENATIVE LABS' LATEST PUBLISHED STUDY DEMONSTRATES THE SAFETY AND EFFICACY OF WHARTON'S JELLY CONNECTIVE TISSUE ALLOGRAFT FOR ROTATOR CUFF TEARS

Retrieved on: 
Thursday, April 4, 2024
Knee, MDPI, Stiffness, Shoulder, Safety, Hip, Wharton's jelly, Rotator cuff, Patient, Research, Rehabilitation, Quality of life, Manager, Efficacy, WOMAC, Regenerative medicine, Quality, Literature, Spine, Orthopedic surgery, Pain, Calendar, Physician, Injury, WJ, Medicine, Dentistry

PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.

Key Points: 
  • PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.
  • Patients in need of rotator cuff repairs often seek minimally invasive options, making Wharton's Jelly a promising alternative for musculoskeletal defects.
  • Utilizing the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life."
  • The study titled "Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears," was published by MDPI and can be accessed in its entirety here.

Quthero Welcomes Dr. Omar Ibrahimi as Chief Medical Director

Retrieved on: 
Tuesday, April 2, 2024
Mohs surgery, Regeneration, Trust, Bruise, Patient, Harvard University, American Academy, Red, Laser, Doctor of Philosophy, MD, American College, Regenerative medicine, Society, Skin, Scar, Physician

TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.

Key Points: 
  • TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.
  • Quthero proudly announces that renowned dermatologist, Dr. Omar Ibrahimi, joins the team as Chief Medical Director.
  • Dr. Ibrahimi, a Harvard-trained, board-certified dermatologist, is the founder and medical director of the Connecticut Skin Institute with over 20 years of experience.
  • "It is a privilege and a great honor to have Dr. Ibrahimi join Quthero to lead the launch of Quthero's post-procedure products as a Chief Medical Director.

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Retrieved on: 
Tuesday, March 26, 2024
Well, Dicarboxylic acid, University, Culture, B cell, Ajinomoto, Growth, Cell, Drug discovery, Biomedical Research, Active ingredient, Good manufacturing practice, Research, GMP, University of Tokyo, Regenerative medicine, API, Good, Amino acid, Multimedia, IPSC, Fine chemical

TOKYO, March 26, 2024  /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Key Points: 
  • TOKYO, March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium.
  • The product line-up of StemFit™ is ideal for regenerative medicine, drug discovery and disease modeling.
  • Additionally, it also enhances further manufacturing of cellular medicines, ensuring superior performance and reliability in iPSC culture.
  • The Group's expertise in GMP API production contributes to the superior performance of the StemFit™ medium, ensuring it meets the highest industry standards.

Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, University, Qiagen, Breast cancer, PerkinElmer, Lung cancer, Medical device, Research, Government, Burn, Drug discovery, Health, Pressure, Growth, Prevalence, Organization, Learning, Figure, Prostate cancer, The BMJ, Tufts University, Incidence, Thermo Fisher Scientific, COVID-19, Danaher Corporation, Conditional sentence, American Cancer Society, RNA, DNA, Female, Robotics, Cancer, Software, Wyss Institute, Laboratory, Woman, Regenerative medicine, Harvard University, Drug development, Xenobot, Medical journal, Pharmaceutical industry

DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.
  • The molecular robotics market is expected to witness a CAGR of 18% over the forecast period.
  • Active participation of universities in drug research and molecular robotics is also supporting the growth of the studied market.
  • Most of the players focus on bringing technologically advanced products into the market to acquire the maximum market share.